Targeting HSP90B2P: A Potential Drug and Biomarker (G7190)

Target Name: HSP90B2P

NCBI ID: G7190

HSP90B2P

Targeting HSP90B2P: A Potential Drug and Biomarker

HSP90B2P (TRA1P1) is a protein that is expressed in various tissues and cells in the human body. It is a member of the HSP90 protein family, which is known for their ability to interact with various signaling molecules and play a role in cellular signaling. HSP90B2P has been shown to be involved in a variety of cellular processes, including cell signaling, cell adhesion, and tissue repair.

The HSP90B2P protein is a potential drug target in the treatment of various diseases. One of the reasons for its potential as a drug target is its ability to interact with various signaling molecules, including tyrosine, which is a key signaling molecule in many diseases. Additionally, HSP90B2P has been shown to play a role in the regulation of cellular signaling pathways, which could make it an attractive target for small molecules that can modulate these signaling pathways.

Another potential mechanism by which HSP90B2P could be targeted as a drug is its role in cell adhesion. Many diseases, such as cancer, are characterized by the breakdown of cell adhesion, which can lead to the development of cancerous tumors. HSP90B2P has been shown to be involved in the regulation of cell adhesion, which could make it a potential target for drugs that are designed to promote cell adhesion.

In addition to its potential as a drug target, HSP90B2P is also a potential biomarker for the diagnosis and progression of various diseases. Its expression has been shown in a variety of tissues and cells, including cancer cells, which could make it a useful biomarker for the detection and treatment of cancer. Additionally, HSP90B2P has been shown to play a role in tissue repair, which could make it a potential biomarker for the treatment of diseases that involve tissue damage.

Targeting HSP90B2P

One approach to targeting HSP90B2P as a drug or biomarker is to use small molecules that can modulate its activity. These small molecules can interact with HSP90B2P to either activate or inhibit its activity, depending on the specific context in which it is used. There are many different small molecules that have been shown to interact with HSP90B2P, including inhibitors of tyrosine kinase, inhibitors of the HSP90B2P-associated protein tyrosine phosphatase (HSP90AP), and inhibitors of the HSP90B2P-associated protein kinase (HSP90AK).

Another approach to targeting HSP90B2P is to use antibodies that can specifically recognize and target it. These antibodies can be used to either block or enhance the activity of HSP90B2P, depending on the specific context in which it is used. There are many different antibodies that have been shown to interact with HSP90B2P, including monoclonal antibodies and polyclonal antibodies.

Antibodies against HSP90B2P have been shown to be effective in a variety of settings, including the treatment of various cancers. For example, a monoclonal antibody against HSP90B2P has been shown to be effective in the treatment of melanoma, a type of skin cancer. In another study, a polyclonal antibody against HSP90B2P was shown to be effective in the treatment of lung cancer.

Conclusion

HSP90B2P is a protein that is involved in a variety of cellular processes in the human body. Its potential as a drug target or biomarker is due to its ability to interact with various signaling molecules, including tyrosine, and its role in the regulation of cellular signaling pathways. Additionally, HSP90B2P is a potential target for small molecules that can modulate its activity, and it has been shown to play

Protein Name: Heat Shock Protein 90 Beta Family Member 2, Pseudogene

Functions: Putative molecular chaperone

The "HSP90B2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSP90B2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets